Royal Bank of Canada
CLDX icon

Royal Bank of Canada’s Celldex Therapeutics CLDX Stock Holding History

Royal Bank of Canada’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Sell
502
-1,790
-78% -$48.8K ﹤0.01% 5983
2025
Q4 		$62K Sell
2,292
-43,109
-95% -$1.14M ﹤0.01% 5446
2025
Q3 		$1.17M Sell
45,401
-5,214
-10% -$121K ﹤0.01% 3850
2025
Q2 		$1.03M Buy
50,615
+50,051
+8,874% +$974K ﹤0.01% 3874
2025
Q1 		$10K Sell
564
-2,466
-81% -$55.1K ﹤0.01% 6142
2024
Q4 		$76K Sell
3,030
-4,723
-61% -$128K ﹤0.01% 5481
2024
Q3 		$263K Buy
7,753
+1,127
+17% +$42.9K ﹤0.01% 4597
2024
Q2 		$245K Buy
6,626
+4,755
+254% +$179K ﹤0.01% 4589
2024
Q1 		$78K Sell
1,871
-13,114
-88% -$539K ﹤0.01% 5326
2023
Q4 		$594K Buy
14,985
+7,217
+93% +$212K ﹤0.01% 4122
2023
Q3 		$214K Buy
7,768
+2,749
+55% +$86.2K ﹤0.01% 4739
2023
Q2 		$170K Buy
5,019
+2,407
+92% +$81.1K ﹤0.01% 4899
2023
Q1 		$94K Sell
2,612
-2,769
-51% -$119K ﹤0.01% 5228
2022
Q4 		$240K Buy
5,381
+4,788
+807% +$171K ﹤0.01% 4721
2022
Q3 		$17K Buy
593
+291
+96% +$8.92K ﹤0.01% 6207
2022
Q2 		$8K Sell
302
-2,527
-89% -$73.4K ﹤0.01% 6455
2022
Q1 		$96K Sell
2,829
-6,715
-70% -$215K ﹤0.01% 5682
2021
Q4 		$368K Buy
9,544
+4,357
+84% +$190K ﹤0.01% 4749
2021
Q3 		$280K Buy
5,187
+2,503
+93% +$117K ﹤0.01% 4856
2021
Q2 		$90K Buy
+2,684
New +$73.7K ﹤0.01% 5676
2021
Q1 		– Sell
-245
Closed -$4K – 7448
2020
Q4 		$4K Buy
245
+232
+1,785% +$4.17K ﹤0.01% 6721
2020
Q3 		$0 Sell
13
-259
-95% -$3.03K ﹤0.01% 6652
2020
Q2 		$3K Sell
272
-1,155
-81% -$5.12K ﹤0.01% 6167
2020
Q1 		$2K Buy
1,427
+942
+194% +$2.13K ﹤0.01% 6277
2019
Q4 		$1K Sell
485
-84
-15% -$195 ﹤0.01% 6633
2019
Q3 		$1K Buy
569
+556
+4,277% +$1.29K ﹤0.01% 6412
2019
Q2 		$0 Hold
13
– – ﹤0.01% 6893
2019
Q1 		$0 Sell
13
-29
-69% -$153 ﹤0.01% 6828
2018
Q4 		$0 Buy
42
+29
+223% +$142 ﹤0.01% 6781
2018
Q3 		$0 Sell
13
-59
-82% -$413 ﹤0.01% 6732
2018
Q2 		$0 Buy
+72
New +$962 ﹤0.01% 6537
2018
Q1 		– Sell
-35
Closed -$1K – 6377
2017
Q4 		$1K Sell
35
-889
-96% -$38.1K ﹤0.01% 6367
2017
Q3 		$39K Buy
924
+299
+48% +$11.2K ﹤0.01% 5560
2017
Q2 		$23K Buy
625
+272
+77% +$12K ﹤0.01% 5480
2017
Q1 		$19K Buy
353
+13
+4% +$677 ﹤0.01% 5644
2016
Q4 		$18K Sell
340
-69
-17% -$3.92K ﹤0.01% 5827
2016
Q3 		$25K Buy
409
+88
+27% +$5.48K ﹤0.01% 5457
2016
Q2 		$21K Buy
321
+29
+10% +$1.84K ﹤0.01% 5488
2016
Q1 		$17K Buy
292
+144
+97% +$16.2K ﹤0.01% 5551
2015
Q4 		$35K Buy
148
+9
+6% +$1.96K ﹤0.01% 5481
2015
Q3 		$21K Buy
139
+47
+51% +$13.3K ﹤0.01% 5551
2015
Q2 		$35K Buy
92
+63
+217% +$25K ﹤0.01% 5408
2015
Q1 		$12K Sell
29
-200
-87% -$71.5K ﹤0.01% 5511
2014
Q4 		$63K Buy
229
+199
+663% +$49.5K ﹤0.01% 4944
2014
Q3 		$6K Sell
30
-70
-70% -$15.3K ﹤0.01% 5603
2014
Q2 		$24K Buy
100
+80
+400% +$18.1K ﹤0.01% 5128
2014
Q1 		$6K Sell
20
-100
-83% -$38.3K ﹤0.01% 5534
2013
Q4 		$43K Sell
120
-225
-65% -$86.7K ﹤0.01% 4956
2013
Q3 		$183K Buy
345
+265
+331% +$90.9K ﹤0.01% 4137
2013
Q2 		$19K Buy
+80
New +$15.8K ﹤0.01% 5041

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Royal Bank of Canada's CLDX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Celldex Therapeutics (CLDX) stake by 78% in Q1 2026, selling an estimated $48.8K and leaving 502 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #5983.

Royal Bank of Canada first reported a position in CLDX in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.17M in Q3 2025. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Royal Bank of Canada held 502 shares of Celldex Therapeutics worth $16K as of Q1 2026.
  • Royal Bank of Canada sold 1,790 Celldex Therapeutics shares in Q1 2026, an estimated $48.8K.
  • Celldex Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5983 holding.
  • Royal Bank of Canada first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's Celldex Therapeutics position peaked at $1.17M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.